<DOC>
	<DOCNO>NCT02074982</DOCNO>
	<brief_summary>This study ass efficacy secukinumab , compare ustekinumab , patient plaque-type psoriasis</brief_summary>
	<brief_title>Efficacy Secukinumab Compared Ustekinumab Patients With Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>patient moderate severe plaque type psoriasis least 6 month randomization patient eligible systemic therapy inadequately control psoriasis form sporiasis plaque type psoriasis previous exposure secukinumab , ustekinumab , biologic drug target ( IL ) 17A IL17RA Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>chronic plaque type psoriasis , secukinumab , ustekinumab , inflammatory skin disease , scale</keyword>
</DOC>